Pretax income is the income that a company earns before paying income taxes. Akari Therapeutics's pretax income for the
three
months ended in Sep. 2024 was $-2.90 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-20.16 Mil.
Akari Therapeutics's pretax margin was %.
Akari Therapeutics Pre-Tax Income Historical Data
The historical data trend for Akari Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akari Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Akari Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's Pre-Tax Income falls into.
Akari Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Akari Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akari Therapeutics (NAS:AKTX) Pre-Tax Income Explanation
Akari Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akari Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Akari Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKTX has been successfully added to your 